Bioventus Inc.
BVS Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$14.96
KIRA · Stoqly’s AI analyst, in plain words
- Bioventus Inc. had $568M of revenue in fiscal 2025, down 0.9% on the year before. Over five years, revenue changed +12.1% a year on average.
- Its operating margin was 9.5%, up 12.2 pts: of every 100 in sales, about 10 is left after running the business.
- Bioventus Inc. made $22.7M of net profit in fiscal 2025.
- Free cash flow was $72.1M in fiscal 2025, 12.7% of revenue.
- Bioventus Inc. owes $252M more than it holds in cash, about 2.5 years of operating profit.
Market cap
$1.1B
P/E
19.4x
Revenue
$568M
Net income
$22.7M
Free cash flow
$72.1M
Operating margin
9.5%
Bioventus Inc. in 30 seconds · fiscal 2025
Are sales growing?
−0.9%
No. Sales fell 0.9% last year.
Does it make a profit?
4.0%
A little. It keeps 4.0% of every sale as profit.
Does profit turn into cash?
12.7%
Yes. 12.7% of sales ends up as free cash.
Is debt under control?
2.5x
Keep an eye on it. Repaying its debt would take 2.5 years of operating profit.
How healthy are the accounts?
8 / 9
Solid. It passes 8 of 9 health tests.
How is the share priced?
19.4x
One share costs 19.4 times its yearly profit per share.
What Bioventus Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Bioventus Inc.
- CIK
- 0001665988
Bioventus Inc. · BVS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $431M | $512M | $512M | $573M | $568M |
| Revenue growth | 34.2% | 18.8% | 0.0% | 11.9% | −0.9% |
| Gross margin | 70.3% | 64.6% | 64.1% | 67.7% | 68.3% |
| Operating margin | 2.8% | −32.7% | −16.0% | −2.7% | 9.5% |
| Net income | $19.4M | −$159M | −$156M | −$36.1M | $22.7M |
| Net margin | 4.5% | −31.0% | −30.5% | −6.3% | 4.0% |
| Diluted EPS | −$0.15 | −$2.59 | −$2.49 | −$0.56 | $0.33 |
| Cash | |||||
| Cash from operations | $23.0M | −$13.5M | $15.3M | $38.8M | $74.7M |
| Capital expenditure | $13.5M | $1.5M | $7.4M | $1.0M | $2.6M |
| Free cash flow | $9.5M | −$15.0M | $8.0M | $37.8M | $72.1M |
| FCF margin | 2.2% | −2.9% | 1.6% | 6.6% | 12.7% |
| Share count change | — | 35.0% | 2.1% | 3.0% | 6.8% |
| Debt and strength | |||||
| Cash and short-term investments | $43.9M | $30.2M | $37.0M | $41.6M | $51.2M |
| Debt incl. finance leases | $358M | $418M | $406M | $346M | $304M |
| Shareholders' equity | $459M | $325M | $174M | $148M | $184M |
| Net debt / EBITDA | 6.7x | — | — | 8.9x | 2.5x |
| Current ratio | 1.5x | 0.9x | 1.5x | 1.3x | 1.7x |
| Returns and quality | |||||
| Return on capital | 1.6% | −18.5% | −12.1% | −2.7% | 12.6% |
| Return on equity | 4.2% | −40.5% | −62.6% | −22.5% | 13.7% |
| Piotroski F-score | 4 | 2 | 4 | 6 | 8 |
| Altman Z'' | 1.3 | −1.0 | −0.9 | −0.9 | 0.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.3M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Bioventus Inc. · BVS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $14.96 a share, the company is worth $1.1B: 19.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001665988). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.